Belite Bio (NASDAQ:BLTE) highlighted progress for its lead drug candidate tinlarebant during the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference, outlining late-stage clinical devel ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the completion of the adult dose escalation portion of the STELLAR Phase 1/2 clinical ...

Please provide your email address to receive an email when new articles are posted on . Gildeuretinol, an oral therapy for Stargardt disease, received rare pediatric disease and fast track ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Belite Bio, Inc., a clinical-stage biopharmaceutical company focusing on treatments for degenerative retinal diseases, announced that it will present two posters at the upcoming ARVO Annual Meeting ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There were no serious adverse events reported in the six ...

Emixustat presents significant market potential due to its novel mechanism targeting unmet needs in retinal diseases like geographic atrophy and Stargardt. Its oral administration enhances patient ...

Ocugen Inc (NASDAQ:OCGN) shares are trading higher during Monday’s session after the company received clearance from the U.S. FDA for its Investigational New Drug amendment to start a Phase 2/3 ...

SAN FRANCISCO — A modified form of vitamin A designed to be taken orally has been found to slow the rate of retinal degeneration in patients with Stargardt disease, a rare genetic eye disease that can ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, announced the completion of the adult dose escalation portion of the STELLAR phase 1/2 clinical trial ...